STAT+: Pharmalittle: Japan panel nixes Biogen Alzheimer’s drug; Oxfam urges SEC to probe Moderna over patent dispute remarks

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until a holiday break arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is cinnamon hazelnut (which may soon be in short supply, given the incredible shrinking Turkish economy). Meanwhile, here are some tidbits to help you along on your own journey. Speaking of which, we will hit the proverbial pause button to enjoy a respite. In other words, we will return on Jan. 3. Until then, we hope you have some time to enjoy yourselves. And of course, stay safe — wear a mask. See you next year, as they say …

The U.S. government expects to have about 4 million courses of Covid-19 treatments on hand by the end of January, including about 3 million courses of the Merck (MRK) pill and 250,000 of the Pfizer (PFE) pill, Bloomberg News reports. France, however, has cancelled its order for the Merck pill following disappointing trial data, becoming the first country to publicly acknowledge this step after the company released data in late November suggesting its drug was markedly less effective than previously thought, Reuters explains. France had placed an early order for 50,000 doses of the drug, known as molnupiravir.

Continue to STAT+ to read the full story…

STAT+: Pharmalittle: Japan panel nixes Biogen Alzheimer’s drug; Oxfam urges SEC to probe Moderna over patent dispute remarks

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top